Pharmacological Treatment of Autism Spectrum Disorder: A Systematic Review of Treatment Guidelines

Abstract

Introduction

Currently available systematic reviews on the pharmacological treatment of autism spectrum disorder (ASD) do not encompass all the evidence, as they exclude guidelines issued by national or local authorities that are not indexed in search engines such as PubMed.

Methods

A systematic literature search was conducted to identify clinical guidelines on this topic using EMBASE, Medline, and PsycINFO. A manual search was also performed to identify guidelines by national or local authorities not included in the aforementioned databases.

Results

Thirty-eight guidelines were identified through manual search, including 27 items through search engines, 2 general guidelines, and 9 government agency guidelines. Many guidelines recommended risperidone (N=16) for the characteristic behaviors of ASD core features. For attention-deficit/hyperactivity disorder (ADHD) features, methylphenidate was most frequently recommended (N=23) for both inattention (N=6) and hyperactivity/impulsivity (N=16). Risperidone was also frequently recommended for maladaptive behaviors (N=33).

Discussion

A comprehensive literature search identified treatment guidelines for ASD issued by local or national administrative bodies that were not captured through search engines alone. There was some consensus among the guidelines on the use of psychotropics in alleviating specific features of ASD. However, physicians need to be aware of the lack of high-quality evidence supporting these recommendations.

Keywords

autistic disorders - risperidone (risperdal) - attention-deficit/hyperactivity disorder(ADHD)

Publikationsverlauf

Eingereicht: 06. Juni 2024
Eingereicht: 16. Dezember 2024

Angenommen: 31. Dezember 2024

Artikel online veröffentlicht:
31. Januar 2025

• References

• 1 American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Arlington, VA: American Psychiatric Association; 2013
• 2 Salpekar JA, Scahill L. Psychopharmacology management in autism spectrum disorder. Pediatr Clin North Am 2024; 71: 283-299
• 3 Wickstrom J, DellʼArmo K, Salzman E. et al. Systematic review: Recommendations for rehabilitation in ASD and ID from clinical practice guidelines. Arch Rehabil Res Clin Transl 2021; 3: 10014
• 4 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021; 372: n71
• 5 Croen LA, Zerbo O, Qian Y. et al. The health status of adults on the autism spectrum. Autism 2015; 19: 814-823
• 6 Lai MC, Kassee C, Besney R. et al. Prevalence of co-occurring mental health diagnoses in the autism population: A systematic review and meta-analysis. The Lancet Psychiatry 2019; 6: 819-829
• 7 Tsai LY. Autistic Disorder. In: Wiener JM, Dulcan MK, eds. The American Psychiatric Publishing textbook of child and adolescent psychiatry, 3rd ed. American Psychiatric Publishing Inc; 2004: 261-316
• 8 Filipek PA, Steinberg-Epstein R, Book TM. Intervention for autistic spectrum disorders. NeuroRx 2006; 3: 207-216
• 9 Carr JE, LeBlanc LA. Autism spectrum disorders in early childhood: An overview for practicing physicians. Prim Care 2007; 34: 343-359
• 10 Gleason MM, Egger HL, Emslie GJ. et al. Psychopharmacological treatment for very young children: Contexts and guidelines. J Am Acad Child Adolesc Psychiatry 2007; 46: 1532-1572
• 11 Schapiro ML, Wasserman S, Hollander E. Treatment of Autism With Selective Serotonin Reuptake Inhibitors and Other Antidepressant. In: Hollander E, Anagnostou, E., eds. Clinical manual for the treatment of autism. American Psychiatric Publishing; 2007: 51-80
• 12 Anagnostou E, Fisher AJ, Hollamder E. Treatment of Autism With Anticonvulsants and Mood Stabilizers. In: Hollander E, Anagnostou E, eds. Clinical manual for the treatment of autism. American Psychiatric Publishing; 2007: 81-98
• 13 Posey D, Stigler KA, Erickson CA. et al Treatment of Autism With Antipsychotics. In: Hollander E, Anagnostou E, eds. Clinical manual for the treatment of autism. American Psychiatric Publishing; 2007: 99-120
• 14 Chez MG, Coughlin C, Kominsky M. Cholinesterase Inhibitor Therapy in Patients With Autism Spectrum Disorders. In: Hollander E, Anagnostou E, eds. Clinical manual for the treatment of autism. American Psychiatric Publishing; 2007: 121-130
• 15 Poncin Y, Scahill L. Stimulants and Nonstimulants in the Treatment of Hyperactivity in Autism. In: Hollander E, Anagnostou E, eds. Clinical manual for the treatment of autism. American Psychiatric Publishing; 2007: 131-152
• 16 the Council on Children With Disabilities. Myers SC, Johnson CP. Management of children with autism spectrum disorders. Pediatrics 2007; 120: 1162-1182
• 17 Tsai LY. Asperger syndrome and medication treatment. Focus on autism and other developmental disabilities 2007; 22: 138-148
• 18 Golombek AA, King B. Pharmacotherapy. In: Dryden-Edwards RC, Combrinck-Graham, L, eds. Developmental disabilities from childhood to adulthood: What works for psychiatrists in community and institutional settings. Johns Hopkins University Press; 2010: 271-295
• 19 Singh NN, Lancioni GE, Winton ASW. et al. Aggression, Tantrums, and Other Externally Driven Challenging Behaviors. In: Matson JL, Sturmey P, eds. International handbook of autism and pervasive developmental disorders. New York: Springer; 2011: 413-435
• 20 Furniss F, Biswas AB, Bezilla B. et al. Self-Injurious Behavior: II. Pharmacological and Integrated Treatments. In: Matson JL, Sturmey P, eds. International handbook of autism and pervasive developmental disorders. New York: Springer; 2011: 453-462
• 21 Mohiuddin S, Bobak S, Gih D. et al. Autism Spectrum Disorders: Comorbid Psychopathology and Treatment. In: Matson JL, Sturmey P, eds. International handbook of autism and pervasive developmental disorders. New York: Springer; 2011: 463-478
• 22 Scahill L, Boorin GS. Psychopharmacology in Children with PDD: Review of Current Evidence. In: Brian R, Peter D, Domenic VC, Fred RV, eds. Evidence-based practices and treatments for children with autism. New York: Springer; 2011: 231-244
• 23 Missouri Autism Guidelines Initiative. Autism spectrum disorders: Guide to evidence-based intervention. 2012
• 24 National Institute for Health and Care Excellence. Autism spectrum disorder in adults: Diagnosis and management. 2012
• 25 Siegel M. Psychopharmacology of autism spectrum disorder: Evidence and practice. Child Adolesc Psychiatr Clin N Am 2012; 21: 957-973
• 26 Manning-Courtney P, Murray D, Currans K. et al. Autism spectrum disorders. Curr Probl Pediatr Adolesc Health Care 2013; 43: 2-11
• 27 National Institute for Health and Care Excellence. Autism spectrum disorder in under 19s: Support and management. 2013
• 28 Swedish agency for health technology assessment of social services. Autism spectrum disorders diagnosis and interventions, organization of care and patient involvement. 2013
• 29 Volkmar F, Siegel M, Woodbury-Smith M. et al. Psychopharmacological Treatment of Asperger Syndrome In: McPartland JC, Klin A, Volkmar FR, eds. Asperger syndrome: Assessing and treating high-functioning autism spectrum disorders, 2nd ed. The Guilford Press; 2014: 280-310
• 30 Veereman G, Henningsen KH, Eyssen M. et al. Management of autism in children and young people: A good clinical practice guideline. 2014
• 31 Volkmar F, Siegel M, Woodbury-Smith M. et al. Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 2014; 53: 237-257
• 32 Ministries of Health and Education. New Zealand autism spectrum disorder guideline (2nd ed) 2016; 132-161
• 33 Pharmacological interventions for children and young people. In: Scottish Intercollegiate Guidelines Network., ed. SIGN 145 Assessment, diagnosis and interventions for autism spectrum disorders. 2016: 32-36 Available at https://www.sign.ac.uk/assets/sign145.pdf
• 34 Pharmacological interventions for adults In: Scottish Intercollegiate Guidelines Network., ed. SIGN 145 Assessment, diagnosis and interventions for autism spectrum disorders. 2016: 37-39 Available at https://www.sign.ac.uk/assets/sign145.pdf
• 35 Choueiri RN, Zimmerman AW. New Assessments and Treatments in ASD. Curr Treat Options Neurol 2017; 19
• 36 National Consultation Meeting for Developing IAP Guidelines on Neuro Developmental Disorders under the aegis of IAP Childhood Disability Group and the Committee on Child Development and Neurodevelopmental Disorders. Consensus statement of the Indian Academy of Pediatrics on evaluation and management of autism spectrum disorder. Indian Pediatr 2017; 54: 385-393
• 37 Developmental Disabilities: Intellectual Disability and Autism. In: Schroeder CS, Smith-Boydston JM, eds. Assessment and treatment of childhood problems: A clinicianʼs guide, 3rd ed. 2017: 389-414
• 38 Baumer N, Spence SJ. Evaluation and management of the child with autism spectrum disorder. Continuum (Minneap Minn) 2018; 24: 248-275
• 39 Chaplin S. BAP consensus guidelines on autism spectrum disorder. Prescriber 2018; 29: 13-17
• 40 Howes OD, Rogdaki M, Findon JL. et al. Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. J Psychopharmacol 2018; 32: 3-29
• 41 Ip A, Zwaigenbaum L, Brian JA. Post-diagnostic management and follow-up care for autism spectrum disorder. Paediatr Child Health 2019; 24: 461-477
• 42 Subramanyam AA, Mukherjee A, Dave M. et al. Clinical practice guidelines for autism spectrum disorders. Indian J Psychiatry 2019; 61: 254-269
• 43 Hyman SL, Levy SE, Myers SM. et al. Identification, evaluation, and management of children with autism spectrum disorder. Pediatrics 2020;
• 44 Young S, Hollingdale J, Absoud M. et al. Guidance for identification and treatment of individuals with attention deficit/hyperactivity disorder and autism spectrum disorder based upon expert consensus. BMC Med 2020; 18
• 45 Dubai Health Authority. Dubai clinical practice guidelines for autism spectrum disorder (ASD) in children and adolescents (from birth to 18 years of age) version 1. 2021
• 46 Fuentes J, Hervas A, Howlin P. ESCAP practice guidance for autism: A summary of evidence-based recommendations for diagnosis and treatment. Eur Child Adolesc Psychiatry 2021; 30: 961-984
• 47 Long M, Register-Brown K. Autism spectrum disorder. Pediatr Rev 2021; 42: 360-374
• 48 National Collaborating Centre for Mental Health. Autism – management of autism in children and young people. The British Psychological Society and The Royal College of Psychiatrists. 2021
• 49 Lord C, Charman T, Havdahl A. et al. The Lancet Commission on the future of care and clinical research in autism. Lancet 2022; 399: 271-334
• 50 Deb SS, Roy M, Limbu B. et al. Antidepressants. In: Matson JL, Sturmey P, eds. Handbook of autism and pervasive developmental disorder: Assessment, diagnosis, and treatment. Springer Nature Switzerland AG; 2022: 1139-1156
• 51 Deb SS, Roy M, Limbu B. et al. Anti-Anxiety Medications and Novel Treatments for Autism. In: Matson JL, Sturmey P, eds. Handbook of autism and pervasive developmental disorder: Assessment, diagnosis, and treatment. Switzerland, AG: Springer Nature; 2022: 1157-1172
• 52 Shaw SR, Wang J. Antipsychotic Medications. In: Matson JL, Sturmey P, eds. Handbook of autism and pervasive developmental disorder: Assessment, diagnosis, and treatment. Switzerland: AG: Springer Nature; 2022: 1173-1190
• 53 Rossignol DA, Frye RE. Psychotropic Medications for Sleep Disorders in Autism Spectrum Disorders. In: Matson JL, Sturmey P, eds. Handbook of autism and pervasive developmental disorder: Assessment, diagnosis, and treatment. Switzerland: AG: Springer Nature; 2022: 1191-1217
• 54 Hirota T, King BH. Pharmacological Interventions. In: Spain D, Musich FM, White SW, eds. Psychological therapies for adults with autism. Oxford Academic. 2022: 234-252
• 55 McDougle CJ, Scahill L, Aman MG. et al. Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005; 162: 1142-1148
• 56 McCracken JT, McGough J, Shah B. et al. Research unit on pediatric psychopharmacology autism network. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347: 314-321
• 57 Fung LK, Mahajan R, Nozzolillo A. et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: A systematic review and meta-analysis. Pediatrics 2016; 137: S124-S135
• 58 Ghaleiha A, Ghyasvand M, Mohammadi MR. et al. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial. J Psychopharmacol 2014; 28: 677-685
• 59 Ure A, Cox GR, Haslam R. et al. Acetylcholinesterase inhibitors for autistic spectrum disorders. Cochrane Database Syst Rev 2023; 6: CD013851
• 60 Anagnostou E, Chaplin W, Watner D. et al. Factor analysis of repetitive behaviors in Autism as measured by the Y-BOCS. J Neuropsychiatry Clin Neurosci 2011; 23: 332-339
• 61 Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005; 62: 1266-1274
• 62 Greenhill LL, Abikoff HB, Arnold LE. et al. Medication treatment strategies in the MTA Study: Relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 1996; 35: 1304-1313
• 63 Greenhill LL, Swanson JM, Vitiello B. et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: The MTA titration trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 180-187
• 64 Glennon J, Purper-Ouakil D, Bakker M. et al. Paediatric European Risperidone Studies (PERS): Context, rationale, objectives, strategy, and challenges. Eur Child Adolesc Psychiatry 2014; 23: 1149-1160
• 65 Center for Drug Evaluation and Research. Applicarion Number: NDA 20-272/S-036/041 NDA 20-588/S-024/028/029 NDA 21-444/S-008/015 2006
• 66 Mano-Sousa BJ, Pedrosa AM, Alves BC. et al. Effects of risperidone in autistic children and young adults: A systematic review and meta-analysis. Curr Neuropharmacol 2021; 19: 538-552
• 67 Janssen Pharmaceutical Companies. RISPERDAL-package insert. 2007
• 68 Cohen D, Raffin M, Canitano R. et al. Risperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: A Bayesian meta-analysis of efficacy and secondary effects. Res Autism Spectr Disord 2013; 7: 167-175